Olezarsen sodium
As of the edition of 20 October 2026, Olezarsen sodium is an oligonucleotide: marketed, first approved in 2024 (US); acts on APOC3; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Oligonucleotide
- Brand name
- Tryngolza (autoinjector)
- First approved
- 19 December 2024 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Akcea Therapeutics
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Akcea Therapeutics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product9 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 9 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| APOC3 | Apolipoprotein C-III | P02656 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Akcea Therapeutics | Originator | 2024 to now |